Ceremony for the dispatch of the first batch of Furmonertinib took place on 03:58am

At 03:58am, March 8th, Allist held a ceremony celebrating the dispatch of the first batch of Furmonertinib in its factory in Jiangsu. Just five days after Furmonertinib was approved for marketing in China, Allist finished the production of the first batch of the new drug that was to be delivered to hospitals and pharmacies for sales across the country through the channels of its strategic partners including Shanghai Pharmaceutical Co., Ltd and Shanghai Pharmaceutical Logistics Center Co., Ltd, at a stunning speed.

Furmonertinib is the third generation of epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI). It targets adult patients who have progressed during or after treatment with EGFR-TKI and diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). Available study results show that Furmonertinib will become a strong competitor in the market of third-generation EGFR-TKIs as it has a significant efficacy and favorable safety. This self-developed innovative, effective drug originated in China will bring relief to more patients in need.